{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:49:32Z","timestamp":1793645372423,"version":"4.5.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T00:00:00Z","timestamp":1591056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T00:00:00Z","timestamp":1591056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The atypical antipsychotic clozapine is one of the most potent drugs of its class, yet its precise mechanisms of action remain insufficiently understood. Recent evidence points toward the involvement of endogenous retinoic acid (RA) signaling in the pathophysiology of schizophrenia. Here we investigated whether clozapine may modulate RA-signaling. Effects of clozapine on the catabolism of<jats:italic>all-trans<\/jats:italic>RA (<jats:italic>at<\/jats:italic>-RA), the biologically most active metabolite of Vitamin A, were assessed in murine and human brain tissue and peripheral blood-derived mononuclear cells (PBMC). In patients with schizophrenia with and without clozapine treatment and matched healthy controls,<jats:italic>at<\/jats:italic>-RA serum levels and blood mRNA expression of retinoid-related genes in PBMCs were quantified. Clozapine and its metabolites potently inhibited RA catabolism at clinically relevant concentrations. In PBMC-derived microsomes, we found a large interindividual variability of the sensitivity toward the effects of clozapine. Furthermore,<jats:italic>at<\/jats:italic>-RA and retinol serum levels were significantly lower in patients with schizophrenia compared with matched healthy controls. Patients treated with clozapine exhibited significantly higher<jats:italic>at<\/jats:italic>-RA serum levels compared with patients treated with other antipsychotics, while retinol levels did not differ between treatment groups. Similarly, in patients without clozapine treatment, mRNA expression of RA-inducible targets CYP26A and STRA6, as well as at-RA\/retinol ratio, were significantly reduced. In contrast, clozapine-treated patients did not differ from healthy controls in this regard. Our findings provide the first evidence for altered peripheral retinoid homeostasis in schizophrenia and suggest modulation of RA catabolism as a novel mechanism of action of clozapine, which may be useful in future antipsychotic drug development.<\/jats:p>","DOI":"10.1038\/s41380-020-0791-8","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T10:05:50Z","timestamp":1591092350000},"page":"5417-5428","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Clozapine modulates retinoid homeostasis in human brain and normalizes serum retinoic acid deficit in patients with schizophrenia"],"prefix":"10.1038","volume":"26","author":[{"given":"Francesca","family":"Regen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoleta-Carmen","family":"Cosma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa R.","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Clemens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana","family":"Saksone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Gellrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berk","family":"Uesekes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Minh Tam","family":"Ta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dettling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Heuser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0411-9204","authenticated-orcid":false,"given":"Julian","family":"Hellmann-Regen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,2]]},"reference":[{"key":"791_CR1","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1056\/NEJM199103143241107","volume":"324","author":"RJ Baldessarini","year":"1991","unstructured":"Baldessarini RJ, Frankenburg FR. Clozapine. A novel antipsychotic agent. N Engl J Med. 1991;324:746\u201354.","journal-title":"N Engl J Med"},{"key":"791_CR2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1136\/eb-2014-101813","volume":"17","author":"M Dold","year":"2014","unstructured":"Dold M, Leucht S. Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective. Evid Ment health. 2014;17:33\u20137.","journal-title":"Evid Ment health"},{"key":"791_CR3","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1192\/bjp.bp.115.177261","volume":"209","author":"D Siskind","year":"2016","unstructured":"Siskind D, McCartney L, Goldschlager R, Kisely S. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry: J Ment Sci. 2016;209:385\u201392.","journal-title":"Br J Psychiatry: J Ment Sci"},{"key":"791_CR4","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","volume":"174","author":"OD Howes","year":"2017","unstructured":"Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, et al. treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174:216\u201329.","journal-title":"Am J Psychiatry"},{"key":"791_CR5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jamapsychiatry.2015.2955","volume":"73","author":"MT Samara","year":"2016","unstructured":"Samara MT, Dold M, Gianatsi M, Nikolakopoulou A, Helfer B, Salanti G, et al. Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiatry. 2016;73:199\u2013210.","journal-title":"JAMA Psychiatry"},{"key":"791_CR6","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951\u201362.","journal-title":"Lancet"},{"key":"791_CR7","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/0006-3223(93)90043-D","volume":"34","author":"C Hagger","year":"1993","unstructured":"Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry. 1993;34:702\u201312.","journal-title":"Biol Psychiatry"},{"issue":"Suppl B","key":"791_CR8","first-page":"47","volume":"55","author":"HY Meltzer","year":"1994","unstructured":"Meltzer HY. An overview of the mechanism of action of clozapine. J Clin psychiatry. 1994;55(Suppl B):47\u201352.","journal-title":"J Clin psychiatry"},{"key":"791_CR9","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1159\/000491700","volume":"87","author":"DD Kim","year":"2018","unstructured":"Kim DD, Barr AM, Honer WG, Procyshyn RM. Reversal of dopamine supersensitivity as a mechanism of action of clozapine. Psychother Psychosom. 2018;87:306\u20137.","journal-title":"Psychother Psychosom"},{"key":"791_CR10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/01.pra.0000388627.36781.6a","volume":"16","author":"MR Baig","year":"2010","unstructured":"Baig MR, Navaira E, Escamilla MA, Raventos H, Walss-Bass C. Clozapine treatment causes oxidation of proteins involved in energy metabolism in lymphoblastoid cells: a possible mechanism for antipsychotic-induced metabolic alterations. J Psychiatr Pract. 2010;16:325\u201333.","journal-title":"J Psychiatr Pract"},{"key":"791_CR11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.brainres.2009.05.063","volume":"1283","author":"BC Magliaro","year":"2009","unstructured":"Magliaro BC, Saldanha CJ. Clozapine protects PC-12 cells from death due to oxidative stress induced by hydrogen peroxide via a cell-type specific mechanism involving inhibition of extracellular signal-regulated kinase phosphorylation. Brain Res. 2009;1283:14\u201324.","journal-title":"Brain Res"},{"key":"791_CR12","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1007\/s13311-017-0552-9","volume":"14","author":"FC Nucifora Jr.","year":"2017","unstructured":"Nucifora FC Jr., Mihaljevic M, Lee BJ, Sawa A. Clozapine as a model for antipsychotic development. NeuroTherapeutics: J Am Soc Exp NeuroTherapeutics. 2017;14:750\u201361.","journal-title":"NeuroTherapeutics: J Am Soc Exp NeuroTherapeutics"},{"key":"791_CR13","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-016-0573-z","volume":"13","author":"L Jiang","year":"2016","unstructured":"Jiang L, Wu X, Wang S, Chen SH, Zhou H, Wilson B, et al. Clozapine metabolites protect dopaminergic neurons through inhibition of microglial NADPH oxidase. J Neuroinflamm. 2016;13:110.","journal-title":"J Neuroinflamm"},{"key":"791_CR14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11481-011-9309-0","volume":"7","author":"X Hu","year":"2012","unstructured":"Hu X, Zhou H, Zhang D, Yang S, Qian L, Wu HM, et al. Clozapine protects dopaminergic neurons from inflammation-induced damage by inhibiting microglial overactivation. J NeuroImmune Pharmacol. 2012;7:187\u2013201.","journal-title":"J NeuroImmune Pharmacol"},{"key":"791_CR15","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.biopsych.2014.07.011","volume":"77","author":"J Hall","year":"2015","unstructured":"Hall J, Trent S, Thomas KL, O\u2019Donovan MC, Owen MJ. Genetic risk for schizophrenia: convergence on synaptic pathways involved in plasticity. Biol Psychiatry. 2015;77:52\u201358.","journal-title":"Biol Psychiatry"},{"key":"791_CR16","doi-asserted-by":"crossref","first-page":"7113","DOI":"10.1073\/pnas.1820690116","volume":"116","author":"YT Hsu","year":"2019","unstructured":"Hsu YT, Li J, Wu D, Sudhof TC, Chen L. Synaptic retinoic acid receptor signaling mediates mTOR-dependent metaplasticity that controls hippocampal learning. Proc Natl Acad Sci USA. 2019;116:7113\u201322.","journal-title":"Proc Natl Acad Sci USA"},{"key":"791_CR17","doi-asserted-by":"crossref","first-page":"10454","DOI":"10.1523\/JNEUROSCI.1133-18.2018","volume":"38","author":"LR Zhong","year":"2018","unstructured":"Zhong LR, Chen X, Park E, Sudhof TC, Chen L. Retinoic acid receptor RARalpha-dependent synaptic signaling mediates homeostatic synaptic plasticity at the inhibitory synapses of mouse visual cortex. J Neurosci. 2018;38:10454\u201366.","journal-title":"J Neurosci"},{"key":"791_CR18","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.neuron.2008.08.012","volume":"60","author":"J Aoto","year":"2008","unstructured":"Aoto J, Nam CI, Poon MM, Ting P, Chen L. Synaptic signaling by all-trans retinoic acid in homeostatic synaptic plasticity. Neuron. 2008;60:308\u201320.","journal-title":"Neuron"},{"key":"791_CR19","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1001\/archpsyc.1996.01830070103015","volume":"53","author":"AB Goodman","year":"1996","unstructured":"Goodman AB. Retinoid dysregulation may result in abnormal expression of glutamic acid decarboxylase in schizophrenia. Arch Gen psychiatry. 1996;53:653.","journal-title":"Arch Gen psychiatry"},{"key":"791_CR20","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/ajmg.1320600415","volume":"60","author":"AB Goodman","year":"1995","unstructured":"Goodman AB. Chromosomal locations and modes of action of genes of the retinoid (vitamin A) system support their involvement in the etiology of schizophrenia. Am J Med Genet. 1995;60:335\u201348.","journal-title":"Am J Med Genet"},{"key":"791_CR21","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41380-018-0305-0","volume":"25","author":"WR Reay","year":"2020","unstructured":"Reay WR, Atkins JR, Quide Y, Carr VJ, Green MJ, Cairns MJ. Polygenic disruption of retinoid signalling in schizophrenia and a severe cognitive deficit subtype. Mol Psychiatry. 2020;25:719\u201331.","journal-title":"Mol Psychiatry"},{"key":"791_CR22","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1021\/pr060176l","volume":"5","author":"C Wan","year":"2006","unstructured":"Wan C, Yang Y, Li H, La Y, Zhu H, Jiang L, et al. Dysregulation of retinoid transporters expression in body fluids of schizophrenia patients. J Proteome Res. 2006;5:3213\u20136.","journal-title":"J Proteome Res"},{"key":"791_CR23","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/ajmg.b.30113","volume":"133B","author":"J Feng","year":"2005","unstructured":"Feng J, Chen J, Yan J, Jones IR, Craddock N, Cook EH Jr., et al. Structural variants in the retinoid receptor genes in patients with schizophrenia and other psychiatric diseases. Am J Med Genet Part B Neuropsychiatr Genet. 2005;133B:50\u201353.","journal-title":"Am J Med Genet Part B Neuropsychiatr Genet."},{"key":"791_CR24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/ajmg.1620","volume":"114","author":"H Ishiguro","year":"2002","unstructured":"Ishiguro H, Okubo Y, Ohtsuki T, Yamakawa-Kobayashi K, Arinami T. Mutation analysis of the retinoid X receptor beta, nuclear-related receptor 1, and peroxisome proliferator-activated receptor alpha genes in schizophrenia and alcohol dependence: possible haplotype association of nuclear-related receptor 1 gene to alcohol dependence. Am J Med Genet. 2002;114:15\u201323.","journal-title":"Am J Med Genet"},{"key":"791_CR25","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41380-019-0566-2","volume":"25","author":"WR Reay","year":"2020","unstructured":"Reay WR, Cairns MJ. The role of the retinoids in schizophrenia: genomic and clinical perspectives. Molecular Psychiatry. 2020;25:706\u201318.","journal-title":"Molecular Psychiatry"},{"key":"791_CR26","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/neu.20242","volume":"66","author":"R Blomhoff","year":"2006","unstructured":"Blomhoff R, Blomhoff HK. Overview of retinoid metabolism and function. J Neurobiol. 2006;66:606\u201330.","journal-title":"J Neurobiol"},{"key":"791_CR27","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.pneurobio.2005.03.002","volume":"75","author":"MA Lane","year":"2005","unstructured":"Lane MA, Bailey SJ. Role of retinoid signalling in the adult brain. Prog Neurobiol. 2005;75:275\u201393.","journal-title":"Prog Neurobiol"},{"key":"791_CR28","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.tins.2012.08.005","volume":"35","author":"KD Shearer","year":"2012","unstructured":"Shearer KD, Stoney PN, Morgan PJ, McCaffery PJ. A vitamin for the brain. Trends Neurosci. 2012;35:733\u201341.","journal-title":"Trends Neurosci"},{"key":"791_CR29","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0896-6273(00)80654-6","volume":"21","author":"MY Chiang","year":"1998","unstructured":"Chiang MY, Misner D, Kempermann G, Schikorski T, Giguere V, Sucov HM, et al. An essential role for retinoid receptors RARbeta and RXRgamma in long-term potentiation and depression. Neuron. 1998;21:1353\u201361.","journal-title":"Neuron"},{"key":"791_CR30","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.neuron.2015.03.009","volume":"86","author":"KL Arendt","year":"2015","unstructured":"Arendt KL, Zhang Y, Jurado S, Malenka RC, Sudhof TC, Chen L. Retinoic acid and LTP recruit postsynaptic AMPA receptors using distinct SNARE-dependent mechanisms. Neuron. 2015;86:442\u201356.","journal-title":"Neuron"},{"key":"791_CR31","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/7214","volume":"2","author":"J Corcoran","year":"1999","unstructured":"Corcoran J, Maden M. Nerve growth factor acts via retinoic acid synthesis to stimulate neurite outgrowth. Nat Neurosci. 1999;2:307\u20138.","journal-title":"Nat Neurosci"},{"key":"791_CR32","doi-asserted-by":"crossref","first-page":"16015","DOI":"10.1073\/pnas.0804801105","volume":"105","author":"B Maghsoodi","year":"2008","unstructured":"Maghsoodi B, Poon MM, Nam CI, Aoto J, Ting P, Chen L. Retinoic acid regulates RARalpha-mediated control of translation in dendritic RNA granules during homeostatic synaptic plasticity. Proc Natl Acad Sci USA. 2008;105:16015\u201320.","journal-title":"Proc Natl Acad Sci USA"},{"key":"791_CR33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fnmol.2012.00016","volume":"5","author":"F Sarti","year":"2012","unstructured":"Sarti F, Schroeder J, Aoto J, Chen L. Conditional RARalpha knockout mice reveal acute requirement for retinoic acid and RARalpha in homeostatic plasticity. Front Mol Neurosci. 2012;5:16.","journal-title":"Front Mol Neurosci"},{"key":"791_CR34","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1017\/S095457941500019X","volume":"27","author":"MS Keshavan","year":"2015","unstructured":"Keshavan MS, Mehta UM, Padmanabhan JL, Shah JL. Dysplasticity, metaplasticity, and schizophrenia: Implications for risk, illness, and novel interventions. Dev Psychopathol. 2015;27:615\u201335.","journal-title":"Dev Psychopathol"},{"key":"791_CR35","doi-asserted-by":"crossref","first-page":"7240","DOI":"10.1073\/pnas.95.13.7240","volume":"95","author":"AB Goodman","year":"1998","unstructured":"Goodman AB. Three independent lines of evidence suggest retinoids as causal to schizophrenia. Proc Natl Acad Sci USA. 1998;95:7240\u20134.","journal-title":"Proc Natl Acad Sci USA"},{"key":"791_CR36","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.psychres.2004.11.003","volume":"133","author":"L Rioux","year":"2005","unstructured":"Rioux L, Arnold SE. The expression of retinoic acid receptor alpha is increased in the granule cells of the dentate gyrus in schizophrenia. Psychiatry Res. 2005;133:13\u201321.","journal-title":"Psychiatry Res"},{"key":"791_CR37","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/sj.mp.4001668","volume":"10","author":"AB Goodman","year":"2005","unstructured":"Goodman AB. Microarray results suggest altered transport and lowered synthesis of retinoic acid in schizophrenia. Mol Psychiatry. 2005;10:620\u20131.","journal-title":"Mol Psychiatry"},{"key":"791_CR38","doi-asserted-by":"crossref","first-page":"e0166944","DOI":"10.1371\/journal.pone.0166944","volume":"11","author":"SM Corley","year":"2016","unstructured":"Corley SM, Tsai SY, Wilkins MR, Shannon Weickert C. Transcriptomic analysis shows decreased cortical expression of NR4A1, NR4A2 and RXRB in schizophrenia and provides evidence for nuclear receptor dysregulation. PLoS ONE. 2016;11:e0166944.","journal-title":"PLoS ONE"},{"key":"791_CR39","doi-asserted-by":"crossref","first-page":"14349","DOI":"10.1073\/pnas.94.26.14349","volume":"94","author":"TA Samad","year":"1997","unstructured":"Samad TA, Krezel W, Chambon P, Borrelli E. Regulation of dopaminergic pathways by retinoids: activation of the D2 receptor promoter by members of the retinoic acid receptor-retinoid X receptor family. Proc Natl Acad Sci USA. 1997;94:14349\u201354.","journal-title":"Proc Natl Acad Sci USA"},{"key":"791_CR40","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s40263-016-0316-9","volume":"30","author":"V Lerner","year":"2016","unstructured":"Lerner V, McCaffery PJ, Ritsner MS. Targeting retinoid receptors to treat schizophrenia: rationale and progress to date. CNS Drugs. 2016;30:269\u201380.","journal-title":"CNS Drugs"},{"key":"791_CR41","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.4088\/JCP.12m08160","volume":"74","author":"V Lerner","year":"2013","unstructured":"Lerner V, Miodownik C, Gibel A, Sirota P, Bush I, Elliot H, et al. The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial. J Clin Psychiatry. 2013;74:1224\u201332.","journal-title":"J Clin Psychiatry"},{"key":"791_CR42","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/WNF.0b013e31806450da","volume":"31","author":"V Lerner","year":"2008","unstructured":"Lerner V, Miodownik C, Gibel A, Kovalyonok E, Shleifer T, Goodman AB, et al. Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: a pilot open-label trial. Clin Neuropharmacol. 2008;31:25\u201333.","journal-title":"Clin Neuropharmacol"},{"key":"791_CR43","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1007\/s00429-015-1102-z","volume":"221","author":"PN Stoney","year":"2016","unstructured":"Stoney PN, Fragoso YD, Saeed RB, Ashton A, Goodman T, Simons C, et al. Expression of the retinoic acid catabolic enzyme CYP26B1 in the human brain to maintain signaling homeostasis. Brain Struct Funct. 2016;221:3315\u201326.","journal-title":"Brain Struct Funct"},{"key":"791_CR44","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00429-011-0359-0","volume":"217","author":"YD Fragoso","year":"2012","unstructured":"Fragoso YD, Shearer KD, Sementilli A, de Carvalho LV, McCaffery PJ. High expression of retinoic acid receptors and synthetic enzymes in the human hippocampus. Brain Struct Funct. 2012;217:473\u201383.","journal-title":"Brain Struct Funct"},{"key":"791_CR45","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrn2212","volume":"8","author":"M Maden","year":"2007","unstructured":"Maden M. Retinoic acid in the development, regeneration and maintenance of the nervous system. Nat Rev Neurosci. 2007;8:755\u201365.","journal-title":"Nat Rev Neurosci"},{"key":"791_CR46","doi-asserted-by":"crossref","DOI":"10.1186\/s12868-018-0460-x","volume":"19","author":"V Clemens","year":"2018","unstructured":"Clemens V, Regen F, Le Bret N, Heuser I, Hellmann-Regen J. Anti-inflammatory effects of minocycline are mediated by retinoid signaling. BMC Neurosci. 2018;19:58.","journal-title":"BMC Neurosci"},{"key":"791_CR47","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3233\/JAD-170823","volume":"61","author":"V Clemens","year":"2018","unstructured":"Clemens V, Regen F, Le Bret N, Heuser I, Hellmann-Regen J. Retinoic acid enhances apolipoprotein E synthesis in human macrophages. J Alzheimer\u2019s Dis. 2018;61:1295\u20131300.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"791_CR48","first-page":"634","volume":"17","author":"F Regen","year":"2016","unstructured":"Regen F, Le Bret N, Hildebrand M, Herzog I, Heuser I, Hellmann-Regen J. Inhibition of brain retinoic acid catabolism: a mechanism for minocycline\u2019s pleiotropic actions? World J Biol Psychiatry. 2016;17:634\u201340.","journal-title":"World J Biol Psychiatry"},{"key":"791_CR49","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.taap.2016.12.003","volume":"316","author":"F Regen","year":"2017","unstructured":"Regen F, Herzog I, Hahn E, Ruehl C, Le Bret N, Dettling M, et al. Clozapine-induced agranulocytosis: Evidence for an immune-mediated mechanism from a patient-specific in-vitro approach. Toxicol Appl Pharmacol. 2017;316:10\u201316.","journal-title":"Toxicol Appl Pharmacol"},{"key":"791_CR50","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/exd.12692","volume":"24","author":"F Regen","year":"2015","unstructured":"Regen F, Hildebrand M, Le Bret N, Herzog I, Heuser I, Hellmann-Regen J. Inhibition of retinoic acid catabolism by minocycline: evidence for a novel mode of action? Exp Dermatol. 2015;24:473\u20136.","journal-title":"Exp Dermatol"},{"key":"791_CR51","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s00702-015-1407-3","volume":"122","author":"J Hellmann-Regen","year":"2015","unstructured":"Hellmann-Regen J, Uhlemann R, Regen F, Heuser I, Otte C, Endres M, et al. Direct inhibition of retinoic acid catabolism by fluoxetine. J Neural Transm. 2015;122:1329\u201338.","journal-title":"J Neural Transm"},{"key":"791_CR52","first-page":"634","volume":"17","author":"F Regen","year":"2016","unstructured":"Regen F, Le Bret N, Hildebrand M, Herzog I, Heuser I, Hellmann-Regen J. Inhibition of brain retinoic acid catabolism: a mechanism for minocycline\u2019s pleiotropic actions? World J Biol Psychiatry. 2016;17:634\u201340.","journal-title":"World J Biol Psychiatry"},{"key":"791_CR53","volume":"13","author":"J Ye","year":"2012","unstructured":"Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL. Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC Bioinforma. 2012;13:134.","journal-title":"BMC Bioinforma"},{"key":"791_CR54","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/npp.1993.50","volume":"9","author":"RJ Baldessarini","year":"1993","unstructured":"Baldessarini RJ, Centorrino F, Flood JG, Volpicelli SA, Huston-Lyons D, Cohen BM. Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology. 1993;9:117\u201324.","journal-title":"Neuropsychopharmacology"},{"key":"791_CR55","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0014-2999(78)90334-5","volume":"51","author":"S Wilk","year":"1978","unstructured":"Wilk S, Stanley M. Clozapine concentrations in brain regions: relationship to dopamine metabolite increase. Eur J Pharmacol. 1978;51:101\u20137.","journal-title":"Eur J Pharmacol"},{"key":"791_CR56","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51:9\u201362.","journal-title":"Pharmacopsychiatry"},{"key":"791_CR57","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/BF00427416","volume":"83","author":"J Hyttel","year":"1984","unstructured":"Hyttel J, Overo KF, Arnt J. Biochemical effects and drug levels in rats after long-term treatment with the specific 5-HT-uptake inhibitor, citalopram. Psychopharmacology. 1984;83:20\u201327.","journal-title":"Psychopharmacology"},{"key":"791_CR58","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s00213-005-0209-y","volume":"183","author":"JS Wang","year":"2006","unstructured":"Wang JS, DeVane CL, Gibson BB, Donovan JL, Markowitz JS, Zhu HJ. Population pharmacokinetic analysis of drug-drug interactions among risperidone, bupropion, and sertraline in CF1 mice. Psychopharmacology. 2006;183:490\u20139.","journal-title":"Psychopharmacology"},{"key":"791_CR59","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/0024-3205(86)90281-X","volume":"39","author":"PT Wong","year":"1986","unstructured":"Wong PT, Yoong YL, Gwee MC. Marked variation in diazepam sensitivity in Swiss albino mice. Life Sci. 1986;39:945\u201352.","journal-title":"Life Sci"},{"key":"791_CR60","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/jat\/bkx098","volume":"42","author":"M Nedahl","year":"2018","unstructured":"Nedahl M, Johansen SS, Linnet K. Reference brain\/blood concentrations of citalopram, duloxetine, mirtazapine and sertraline. J Anal Toxicol. 2018;42:149\u201356.","journal-title":"J Anal Toxicol"},{"key":"791_CR61","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/jat\/bkw059","volume":"40","author":"L Skov","year":"2016","unstructured":"Skov L, Holm KM, Johansen SS, Linnet K. Postmortem brain and blood reference concentrations of alprazolam, bromazepam, chlordiazepoxide, diazepam, and their metabolites and a review of the literature. J Anal Toxicol. 2016;40:529\u201336.","journal-title":"J Anal Toxicol"},{"key":"791_CR62","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/jnr.23843","volume":"95","author":"R Takamura","year":"2017","unstructured":"Takamura R, Watamura N, Nikkuni M, Ohshima T. All-trans retinoic acid improved impaired proliferation of neural stem cells and suppressed microglial activation in the hippocampus in an Alzheimer\u2019s mouse model. J Neurosci Res. 2017;95:897\u2013906.","journal-title":"J Neurosci Res"},{"key":"791_CR63","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/glia.20153","volume":"50","author":"ST Dheen","year":"2005","unstructured":"Dheen ST, Jun Y, Yan Z, Tay SS, Ling EA. Retinoic acid inhibits expression of TNF-alpha and iNOS in activated rat microglia. Glia. 2005;50:21\u201331.","journal-title":"Glia"},{"key":"791_CR64","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.tics.2017.06.006","volume":"21","author":"JK Forsyth","year":"2017","unstructured":"Forsyth JK, Lewis DA. Mapping the consequences of impaired synaptic plasticity in schizophrenia through development: an integrative model for diverse clinical features. Trends Cogn Sci. 2017;21:760\u201378.","journal-title":"Trends Cogn Sci"},{"key":"791_CR65","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/978-94-024-0945-1_5","volume":"81","author":"NY Kedishvili","year":"2016","unstructured":"Kedishvili NY. Retinoic acid synthesis and degradation. Subcell Biochem. 2016;81:127\u201361.","journal-title":"Subcell Biochem"},{"key":"791_CR66","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1517\/17425250903032681","volume":"5","author":"JE Thatcher","year":"2009","unstructured":"Thatcher JE, Isoherranen N. The role of CYP26 enzymes in retinoic acid clearance. Expert Opin drug Metab Toxicol. 2009;5:875\u201386.","journal-title":"Expert Opin drug Metab Toxicol"},{"key":"791_CR67","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.urology.2013.10.029","volume":"83","author":"F Regen","year":"2014","unstructured":"Regen F, Heuser I, Herzog I, Hellmann-Regen J. Striking growth-inhibitory effects of minocycline on human prostate cancer cell lines. Urology. 2014;83:509. e501-509. e506","journal-title":"Urology"},{"key":"791_CR68","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.schres.2019.08.005","volume":"212","author":"L Zhang","year":"2019","unstructured":"Zhang L, Zheng H, Wu R, Kosten TR, Zhang XY, Zhao J. The effect of minocycline on amelioration of cognitive deficits and pro-inflammatory cytokines levels in patients with schizophrenia. Schizophrenia Res. 2019;212:92\u201398.","journal-title":"Schizophrenia Res"},{"key":"791_CR69","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pnpbp.2018.04.004","volume":"85","author":"L Zhang","year":"2018","unstructured":"Zhang L, Zheng H, Wu R, Zhu F, Kosten TR, Zhang XY, et al. Minocycline adjunctive treatment to risperidone for negative symptoms in schizophrenia: association with pro-inflammatory cytokine levels. Prog Neuro-Psychopharmacol Biol Psychiatry. 2018;85:69\u201376.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"791_CR70","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.pnpbp.2006.08.013","volume":"31","author":"T Miyaoka","year":"2007","unstructured":"Miyaoka T, Yasukawa R, Yasuda H, Hayashida M, Inagaki T, Horiguchi J. Possible antipsychotic effects of minocycline in patients with schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry. 2007;31:304\u20137.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"791_CR71","doi-asserted-by":"crossref","first-page":"e2699","DOI":"10.1002\/hup.2699","volume":"34","author":"Z Xiong","year":"2019","unstructured":"Xiong Z, Cheng M, Zhu P, Huang S, Guo J, Zhang W, et al. Association of blood cell counts with the risk of olanzapine- or clozapine-induced dyslipidemia in Chinese schizophrenia patients. Hum Psychopharmacol. 2019;34:e2699.","journal-title":"Hum Psychopharmacol"},{"key":"791_CR72","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/dth.12085","volume":"26","author":"JS Lilley","year":"2013","unstructured":"Lilley JS, Linton MF, Fazio S. Oral retinoids and plasma lipids. Dermatol Ther. 2013;26:404\u201310.","journal-title":"Dermatol Ther"},{"key":"791_CR73","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0076-6879(86)23015-3","volume":"123","author":"JL Napoli","year":"1986","unstructured":"Napoli JL. Quantification of physiological levels of retinoic acid. Methods Enzymol. 1986;123:112\u201324.","journal-title":"Methods Enzymol"},{"key":"791_CR74","doi-asserted-by":"crossref","unstructured":"Chan RF, Shabalin AA, Montano C, Hannon E, Hultman CM, Fallin MD et al. Independent methylome-wide association studies of schizophrenia detect consistent case-control differences. Schizophrenia Bull. 2019.","DOI":"10.1093\/schbul\/sbz056"},{"key":"791_CR75","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.pnpbp.2009.08.008","volume":"33","author":"C Wan","year":"2009","unstructured":"Wan C, Shi Y, Zhao X, Tang W, Zhang M, Ji B, et al. Positive association between ALDH1A2 and schizophrenia in the Chinese population. Prog Neuro-Psychopharmacol Biol Psychiatry. 2009;33:1491\u20135.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"791_CR76","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/cts.12616","volume":"12","author":"F Stevison","year":"2019","unstructured":"Stevison F, Kosaka M, Kenny JR, Wong S, Hogarth C, Amory JK, et al. Does in vitro cytochrome P450 downregulation translate to in vivo drug-drug interactions? Preclinical and clinical studies with 13-cis-retinoic acid. Clin Transl Sci. 2019;12:350\u201360.","journal-title":"Clin Transl Sci"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-020-0791-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-020-0791-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-020-0791-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T20:47:05Z","timestamp":1696193225000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-020-0791-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,2]]},"references-count":76,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["791"],"URL":"https:\/\/doi.org\/10.1038\/s41380-020-0791-8","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,2]]},"assertion":[{"value":"12 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}